[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351625-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351625-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","multifunctional-chitosan-doxorubicin-nanocarriers-advancing-targeted-breast-cancer-chemotherapy","Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy","","Breast cancer remains a leading cause of cancer-related mortality worldwide, and chemotherapy is central to clinical management. Doxorubicin shows strong antitumor activity but is constrained by dose-limiting cardiotoxicity, limited tumor selectivity, and rapid multidrug resistance. This review highlights chitosan-based doxorubicin nanocarriers engineered to recognize cancer cell markers, respond to tumor-specific cues like acidic pH and elevated glutathione, and deliver drug combinations that disrupt resistance pathways. It also covers systemic nanoplatforms and localized depots, outlining intracellular delivery from receptor binding to DNA damage and apoptosis, and concludes with translational challenges and future directions toward clinical impact.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/multifunctional-chitosan-doxorubicin-nanocarriers-advancing-targeted-breast-cancer-chemotherapy/351625/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/multifunctional-chitosan-doxorubicin-nanocarriers-advancing-targeted-breast-cancer-chemotherapy/351625.png","ImageObject",300,407,{"name":42,"@type":43},"Đào","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is doxorubicin important in breast cancer chemotherapy?","Question",{"text":63,"@type":64},"Doxorubicin is a long-standing first-line chemotherapeutic with antitumor activity mediated through DNA intercalation and topoisomerase IIa poisoning, as well as intracellular reactive oxygen species generation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limitations restrict doxorubicin’s clinical utility?",{"text":68,"@type":64},"Its use is sharply limited by cumulative, dose-dependent cardiotoxicity that can progress to cardiomyopathy and congestive heart failure, along with acute hematologic effects and the emergence of multidrug resistance.",{"name":70,"@type":61,"acceptedAnswer":71},"How do chitosan-based nanocarriers aim to improve targeted therapy?",{"text":72,"@type":64},"The review describes nanoplatforms designed to recognize cancer cell surface markers, respond to tumor-specific cues such as acidic pH and elevated glutathione, and deliver drug combinations that counter resistance mechanisms while sparing healthy tissue.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351625,1790146385,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Mishra et al. Molecular Cancer (2026) 25:125 [https://doi.org/10.1186/s12943-026-02639-0](https://doi.org/10.1186/s12943-026-02639-0)  \nMolecular Cancer  \nREVIEW Open Access  \nMultifunctional chitosan–doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy  \nGaurav Mishra1†, Muskan Leharwani1†, Taha Alqahtani2, Humood Al Shmrany3, Garima Gupta4,5, Amirhossein Sahebkar6*, Umesh Kumar Patil7 and Prashant Kesharwani1*†  \nAbstract  \nBreast cancer remains one of the leading causes of cancer-related mortality worldwide, with chemotherapy continuing to play a central role in clinical management. Doxorubicin, despite its potent antitumor activity, suffers from severe dose-limiting cardiotoxicity, poor tumor selectivity and the rapid emergence of multidrug resistance. Chitosan, a naturally derived biocompatible polysaccharide, has emerged as a versatile nanocarrier platform capable of addressing these limitations through intelligent design strategies. This review explores how chitosan-based doxorubicin nanoplatforms have been engineered to recognize cancer cell surface markers, respond to tumor-specific cues such as acidic pH and elevated glutathione, and deliver drug combinations that dismantle resistance mechanisms. We examine both systemic nanoparticulate systems and innovative localized depots including injectable gels, implantable matrices and even oral bacteria-assisted carriers that concentrate chemotherapy at the tumor site while sparing healthy tissues. By detailing the intracellular journey of these nanoplatforms from receptor binding to nuclear DNA damage and apoptosis induction, this review illuminates the molecular basis of their enhanced efficacy. Finally, we discuss the translational challenges and future directions needed to bring these promising chitosan nanomedicines from bench to bedside for improved breast cancer outcomes.  \nKeywords Chitosan nanocarriers, Doxorubicin delivery, Breast cancer therapy, Targeted drug delivery, Stimuliresponsive nanoparticles, Combination chemotherapy, Nanomedicine  \n†Gaurav Mishra, Muskan Leharwani and Prashant Kesharwani contributed equally to this work.  \n*Correspondence: Amirhossein Sahebkar[amir_saheb2000@yahoo.com](amir_saheb2000@yahoo.com)[ ](amir_saheb2000@yahoo.com)Prashant Kesharwani [prashantdops@gmail.com](prashantdops@gmail.com)  \nFull list of author information is available at the end of the article  \nIntroduction  \nIn 2022 alone, breast cancer accounted for 2.3 million new diagnoses and approximately 670,000 deaths worldwide, overtaking lung cancer as the single most frequently diagnosed malignancy in women and emerging as the leading cause of female cancer mortality in the majority of countries [1–3] . Recent epidemiological simulations show a very bleak pattern that by the year 2040, there will be more than 3.1 million cases each year and by 2050, the number could go as high as 6 million cases annually, mainly affecting the people in Asia and Africa due to changing lifestyles and  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, vis","cbCaidLVLy58CrDu","https://ap.wps.com/l/cbCaidLVLy58CrDu","pdf",4390319,38,"English","# Abstract\n## Keywords\n## Introduction\n## Doxorubicin and breast cancer treatment","[{\"question\":\"Why is doxorubicin important in breast cancer chemotherapy?\",\"answer\":\"Doxorubicin is a long-standing first-line chemotherapeutic with antitumor activity mediated through DNA intercalation and topoisomerase IIa poisoning, as well as intracellular reactive oxygen species generation.\"},{\"question\":\"What limitations restrict doxorubicin’s clinical utility?\",\"answer\":\"Its use is sharply limited by cumulative, dose-dependent cardiotoxicity that can progress to cardiomyopathy and congestive heart failure, along with acute hematologic effects and the emergence of multidrug resistance.\"},{\"question\":\"How do chitosan-based nanocarriers aim to improve targeted therapy?\",\"answer\":\"The review describes nanoplatforms designed to recognize cancer cell surface markers, respond to tumor-specific cues such as acidic pH and elevated glutathione, and deliver drug combinations that counter resistance mechanisms while sparing healthy tissue.\"}]","Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy | PDF",1790095026,96,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/185d69bb62bfc76910af0c3174e057da.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/131a8815f6f25897c8f888bb7b97c6ce.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4187e9c7ffb7656d8770e352818d515.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee5861a441ab9e3358b9439982dbf82f.webp",980,1306]